Inmune Bio Inc (INMB)

$8.37

-0.43

(-4.89%)

Market is closed - opens 7 PM, 22 Apr 2024

Performance

  • $8.30
    $8.95
    $8.37
    downward going graph

    0.84%

    Downside

    Day's Volatility :7.28%

    Upside

    6.5%

    downward going graph
  • $6.50
    $14.74
    $8.37
    downward going graph

    22.34%

    Downside

    52 Weeks Volatility :55.9%

    Upside

    43.22%

    downward going graph

Returns

PeriodInmune Bio Inc
3 Months
-25.07%
6 Months
16.01%
1 Year
5.28%
3 Years
-63.56%

Highlights

Market Capitalization
160.2M
Book Value
$2.08
Earnings Per Share (EPS)
-1.67
Wall Street Target Price
19.67
Profit Margin
0.0%
Operating Margin TTM
-29925.0%
Return On Assets TTM
-26.79%
Return On Equity TTM
-61.09%
Revenue TTM
155.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-71.1%
Gross Profit TTM
374.0K
Diluted Eps TTM
-1.67
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.19
EPS Estimate Next Year
-1.95
EPS Estimate Current Quarter
-0.44
EPS Estimate Next Quarter
-0.58

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Inmune Bio Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 135.01%

Current $8.37
Target $19.67

Technicals Summary

Sell

Neutral

Buy

Inmune Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inmune Bio Inc
Inmune Bio Inc
-27.78%
16.01%
5.28%
-63.56%
-63.56%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inmune Bio Inc
Inmune Bio Inc
NA
NA
NA
-2.19
-0.61
-0.27
NA
2.08
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inmune Bio Inc
Inmune Bio Inc
Buy
$160.2M
-63.56%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • Vanguard Group Inc

    3.01%
  • BlackRock Inc

    1.43%
  • Rhenman Partners Asset Management AB

    0.99%
  • Geode Capital Management, LLC

    0.94%
  • Janney Montgomery Scott LLC

    0.91%
  • Deutsche Bank AG

    0.61%

Corporate Announcements

  • Inmune Bio Inc Earnings

    Inmune Bio Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.

Organization
Inmune Bio Inc
Employees
11
CEO
Dr. Raymond Joseph Tesi M.D.
Industry
Medical Specialties

FAQs